Zhengda Tianqing, Osaikang... grab 1.5 billion injections!

A few days ago, the official website of the State Food and Drug Administration showed that Liaoning Haisco Pharmaceutical's Palonosetron Hydrochloride Injection was approved as a supplementary application.
In February of this year, Liaoning Haisco Pharmaceutical had already passed a product regulation
.

September 09, 2021, release of drug approval documents pending receipt

Data show that Palonosetron Hydrochloride Injection is a second-generation long-acting 5-HT3 receptor antagonist.
Compared with similar drugs such as ondansetron and granisetron, Palonosetron has a smaller dosage.
The advantages of high plasma protein binding rate and long half-life are superior to traditional 5-HT3 receptor antagonists for acute CINV (chemotherapy-related nausea and vomiting) and delayed CINV, especially for delayed CINV
.

Sales of Palonosetron Hydrochloride Injection in China's Public Medical Institutions in Recent Years (Unit: 100 million yuan)

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

Palonosetron Hydrochloride Injection was developed by Helsinn Healthcare SA and was approved for marketing in China in 2018
.

There are 14 manufacturers of Palonosetron Hydrochloride Injection.
Among them, Qilu Pharmaceutical (Hainan) has the largest market share, accounting for nearly 50%, and Hangzhou Jiuyuan Gene and Zhengda Tianqing Pharmaceutical Group have market shares exceeding 10%.

.

It is worth mentioning that Palonosetron Hydrochloride Injection is the fifth batch of collected varieties, Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group Sichuan Hairong Pharmaceutical, Jiangsu Hengrui Pharmaceutical, Liaoning Haisco Pharmaceutical, Jiangsu Osay Kang Pharmaceutical and Hangzhou Jiuyuan Gene won the bid, and the market structure of this product may change in the future

Source: official website of the State Food and Drug Administration, Mi Nei.